These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17597261)

  • 21. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.
    Divekar AA; Khanna D; Abtin F; Maranian P; Saggar R; Saggar R; Furst DE; Singh RR
    Clin Immunol; 2011 Dec; 141(3):293-303. PubMed ID: 22015344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 23. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
    Iwayama T; Olson LE
    Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease.
    Zoja C; Corna D; Rottoli D; Zanchi C; Abbate M; Remuzzi G
    Kidney Int; 2006 Jul; 70(1):97-103. PubMed ID: 16688113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
    ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
    Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular framework for response to imatinib mesylate in systemic sclerosis.
    Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
    Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of imatinib in the treatment of pulmonary hypertension.
    Mucke H
    Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib treatment of generalized localized scleroderma (morphea).
    Moinzadeh P; Krieg T; Hunzelmann N
    J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732
    [No Abstract]   [Full Text] [Related]  

  • 32. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.
    Casali PG; Bertulli R; Fumagalli E; Coco P; Grosso F; Stacchiotti S
    J Chemother; 2004 Nov; 16 Suppl 4():55-8. PubMed ID: 15688611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
    Bournia VK; Evangelou K; Sfikakis PP
    Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.
    Asano Y; Bujor AM; Trojanowska M
    J Dermatol Sci; 2010 Sep; 59(3):153-62. PubMed ID: 20663647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
    Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
    Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Autophagy in hematologic malignancies].
    Adachi S
    Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
    [No Abstract]   [Full Text] [Related]  

  • 39. Imatinib mesylate: an innovation in treatment of autoimmune diseases.
    Azizi G; Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2013 Sep; 7(3):259-67. PubMed ID: 23947692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.